For PD-1/PD-L1, Peng et al. conducted a systematic search to show the PD-L1 might be a predictive biomarker for EGFR-mutant non-small cell lung cancer treated with EGFR-TKIs [26]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.